Breathing training program for improving exercise capacity in patients with non-cystic fibrosis bronchiectasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research investigates the effects of a home-based breathing and respiratory muscle training program, supported by a health coach, on exercise capacity and lung function in individuals diagnosed with non-cystic fibrosis bronchiectasis. Participants will engage in a structured regimen using LungTrainers to enhance their respiratory muscles and overall clinical status. The study aims to determine if this intervention can lead to significant improvements in the ability to exercise and quality of life for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Mayo Clinic patient with confirmed diagnosis of Non-Cystic Fibrosis Bronchiectasis (non-CFB): Non-CFB as confirmed by clinical history, including cough, shortness of breath, exertional dyspnea, pulmonary function tests, and high-resolution computed tomography. Patients will be considered clinically stable if there is no evidence of an exacerbation or change(s) in medical therapy in the previous three weeks.
* Able and willing to provide informed consent to participate in the study.

Exclusion Criteria:

* Presence of significant coexisting disease, neurological conditions, and/or orthopedic complications that affect ability to undertake exercise.
* Presence of advanced heart failure.
* Current use of antibiotics.
* Acute exacerbation(s) within 3-weeks prior to study commencement.
* Participation within a pulmonary rehabilitation program within 6-months prior to study commencement.

Where it's running

• Mayo Clinic Florida
  Jacksonville, Florida, United States Recruiting

Study contacts

• Principal investigator: Bryan Taylor, PhD — Mayo Clinic

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Galvokimig vs placebo for non-CF bronchiectasis in adults

  This study tests whether Galvokimig can delay the first pulmonary flare compared with placebo in adults with non-CF bronchiectasis.

  Recruiting at 7 sites Phase 2 UCB Pharma · Newport Beach, California and 6 other locations · NCT07720375

• Safety test of HSK31858 in people with non-cystic fibrosis bronchiectasis

  This phase 3 study tests whether HSK31858 is safe for adults with non-cystic fibrosis bronchiectasis who previously participated in the related study.

  Recruiting Phase 3 Haisco Pharmaceutical Group Co., Ltd. · Yixingcun, Jiangxi · NCT07616375

• Azithromycin added to usual care to see if it lowers bronchiectasis flare-ups

  This trial tests whether taking azithromycin daily for a year reduces bronchiectasis-related flare-ups in adults with non-cystic fibrosis bronchiectasis.

  Recruiting Phase 4 Assiut University · Asyut · NCT07608328

• Bronchiectasis Phenotype Identification Model for Adults

  This study tests a baseline classifier to categorize adults with non-cystic fibrosis bronchiectasis into phenotype groups using data collected over time.

  Recruiting Assiut University · Asyut, Assiut Egypt · NCT07599969

• BASE: Aiming to test a simple, objective way to gauge bronchiectasis severity and predict flare-ups

  This study tests a new BASE framework to classify how severe non-cystic fibrosis bronchiectasis is right now and see if it can predict 12 months of worsening or flare-ups.

  Recruiting Assiut University · Asyut, Asyut Egypt · NCT07599839

• Nebulized CSL787 (inhaled IgG) to reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis

  This research will test whether inhaled CSL787 (a nebulized immunoglobulin medicine) can delay or reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis over 6–12 months compared with placebo.

  Recruiting at 13 sites Phase 2 CSL Behring · Queensland and 12 other locations · NCT07048262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.